Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04220632
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04214626
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 100
- Registration Number
- NCT04175431
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Novel Form of Acquired Long QT Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Narrows Institute for Biomedical Research
- Target Recruit Count
- 25
- Registration Number
- NCT04169100
- Locations
- 🇺🇸
VA New York Harbor Healthcare System, NY and Brooklyn Campuses, New York, New York, United States
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT04151082
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
SHR0302 and Steroid As First Line Therapy for Chronic GVHD
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2024-11-13
- Target Recruit Count
- 28
- Registration Number
- NCT04146207
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
🇨🇳Xianmin Song, Shanghai, Shanghai, China
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 15
- Registration Number
- NCT04139304
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1030
- Registration Number
- NCT04100018
- Locations
- 🇺🇸
Local Institution - 0011, San Antonio, Texas, United States
🇺🇸Local Institution - 0081, Santa Monica, California, United States
🇺🇸Local Institution - 0055, Rancho Mirage, California, United States
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT04083898
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.